SCHEMBL2909130

SCHEMBL2909130

CCOC(=O)c1ccc(N(Cc2cccnc2)c2ccc(F)c(OC)c2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.46
GAA P10253 2/20 0.45
POLB P06746 1/20 0.45
ALDH1A1 P00352 5/20 0.43
MAPT P10636 3/20 0.43
USP2 O75604 2/20 0.43
KDM4E B2RXH2 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
NPC1 O15118 1/20 0.43
MAPK1 P28482 1/20 0.43
RAB9A P51151 1/20 0.43
HSD17B10 Q99714 1/20 0.43
NAMPT P43490 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HTT P42858 1/20 0.41
QPCT Q16769 1/20 0.41
CYP1A2 P05177 2/20 0.40
CYP3A4 P08684 2/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2909628 0.93 GRM2 (0.43) KMT2AGAAALDH1A1MAPTKDM4E
SCHEMBL2910364 0.88 TAS2R14 (0.46) GAAALDH1A1MAPTUSP2NAMPT
SCHEMBL1157639 0.83 PDE4B (0.54) KMT2AALDH1A1USP2L3MBTL1NPSR1
SCHEMBL2910411 0.82 GRM2 (0.46) ALDH1A1USP2NAMPTL3MBTL1NPSR1
SCHEMBL2910978 0.82 NAMPT (0.45) POLBALDH1A1MAPTKDM4ESMN1; SMN2
SCHEMBL2905935 0.80 HTT (0.48) ALDH1A1MAPTUSP2MAPK1RAB9A
SCHEMBL1157752 0.80 GRM2 (0.44) KMT2APOLBALDH1A1MAPTUSP2
SCHEMBL4190538 0.79 ALDH1A1 (0.55) KMT2AGAAPOLBALDH1A1MAPT
SCHEMBL3129630 0.79 MAPT (0.44) KMT2AGAAPOLBALDH1A1MAPT
SCHEMBL4193526 0.78 L3MBTL1 (0.48) ALDH1A1MAPTUSP2NPC1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1692109-B1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS MEMORY PHARM CORP (US) 2010-08-18 EP disclosed
US-20050222207-A1 Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs MEMORY PHARMACEUTICAL CORPORATION 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222207-A1 Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs PDE4A, PDE4B, PDE3B KMT2A 1702/4885GAA 1294/4885POLB 1769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.